U.S. Markets close in 2 hrs 45 mins
  • S&P 500

    3,797.40
    +28.93 (+0.77%)
     
  • Dow 30

    31,180.73
    +256.59 (+0.83%)
     
  • Nasdaq

    12,750.14
    +26.67 (+0.21%)
     
  • Russell 2000

    2,148.07
    +1.15 (+0.05%)
     
  • Crude Oil

    65.88
    +2.05 (+3.21%)
     
  • Gold

    1,700.10
    -0.60 (-0.04%)
     
  • Silver

    25.17
    -0.29 (-1.12%)
     
  • EUR/USD

    1.1913
    -0.0066 (-0.5480%)
     
  • 10-Yr Bond

    1.5570
    +0.0070 (+0.45%)
     
  • Vix

    27.25
    -1.32 (-4.62%)
     
  • GBP/USD

    1.3830
    -0.0064 (-0.4578%)
     
  • USD/JPY

    108.2870
    +0.3110 (+0.2880%)
     
  • BTC-USD

    48,207.44
    -1,203.52 (-2.44%)
     
  • CMC Crypto 200

    964.70
    +21.53 (+2.28%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • Nikkei 225

    28,864.32
    -65.79 (-0.23%)
     

Is Homology Medicines (FIXX) Stock a Solid Choice Right Now?

  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

One stock that might be an intriguing choice for investors right now is Homology Medicines, Inc. FIXX. This is because this security in the Medical - Generic Drugs space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.

This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Medical - Generic Drugs space as it currently has a Zacks Industry Rank of 46 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.

Meanwhile, Homology Medicines is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.

Homology Medicines, Inc. Price and Consensus

Homology Medicines, Inc. Price and Consensus
Homology Medicines, Inc. Price and Consensus

Homology Medicines, Inc. price-consensus-chart | Homology Medicines, Inc. Quote

In fact, over the past month, current quarter estimates have narrowed from a loss of 79 cents per share to a loss of 76 cents per share, while current year estimates have narrowed from a loss of $2.94 per share to a loss of $2.82 cents per share. This has helped FIXX to earn a Zacks Rank #2 (Buy), further underscoring the company’s solid position. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

So, if you are looking for a decent pick in a strong industry, consider Homology Medicines. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.

 Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>
 


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Homology Medicines, Inc. (FIXX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research